Department of Immunology, Gynecologic Oncology and Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
b Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Immunol Invest. 2022 Nov;51(8):2215-2225. doi: 10.1080/08820139.2022.2096463. Epub 2022 Jul 7.
CAR T-cell therapy has transformed the treatment of hematological malignancies of the B cell lineage. However, the quest to fulfil the same promise for solid tumors is still in its infancy. This review summarizes some of the challenges that the field is trying to overcome for effective treatment of human carcinomas, including tumor heterogeneity, the paucity of truly tumor-specific targets, immunosuppression and metabolic restrictions at solid tumor beds, and defective T-cell trafficking. All these barriers are being currently investigated and, in some cases, targeted, by multiple independent groups. With clinical interventions against multiple human malignancies and different platforms under accelerated clinical development, the next few years will see an array of cellular therapies, including CAR T-cells, progressively becoming routine interventions to eliminate currently incurable diseases, as it happened with some hematological malignancies.
嵌合抗原受体 T 细胞疗法已经改变了 B 细胞谱系血液恶性肿瘤的治疗方式。然而，为实体瘤实现同样疗效的探索仍处于起步阶段。本综述总结了该领域为有效治疗人类癌瘤而试图克服的一些挑战，包括肿瘤异质性、真正肿瘤特异性靶标的缺乏、实体瘤床的免疫抑制和代谢限制，以及 T 细胞运输缺陷。目前，多个独立的研究小组正在研究并在某些情况下针对这些障碍。随着针对多种人类恶性肿瘤的临床干预措施和不同平台的加速临床开发，未来几年将出现一系列细胞疗法，包括嵌合抗原受体 T 细胞疗法，逐渐成为消除目前无法治愈疾病的常规干预措施，就像一些血液恶性肿瘤那样。
